Centessa Pharmaceuticals (CNTA) Cash & Equivalents (2022 - 2025)
Historic Cash & Equivalents for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $50.8 million.
- Centessa Pharmaceuticals' Cash & Equivalents fell 8713.73% to $50.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.8 million, marking a year-over-year decrease of 8713.73%. This contributed to the annual value of $383.2 million for FY2024, which is 19932.13% up from last year.
- Latest data reveals that Centessa Pharmaceuticals reported Cash & Equivalents of $50.8 million as of Q3 2025, which was down 8713.73% from $44.2 million recorded in Q2 2025.
- Centessa Pharmaceuticals' Cash & Equivalents' 5-year high stood at $544.5 million during Q1 2022, with a 5-year trough of $44.2 million in Q2 2025.
- Its 4-year average for Cash & Equivalents is $253.1 million, with a median of $171.5 million in 2023.
- Per our database at Business Quant, Centessa Pharmaceuticals' Cash & Equivalents surged by 19932.13% in 2024 and then plummeted by 8713.73% in 2025.
- Quarter analysis of 4 years shows Centessa Pharmaceuticals' Cash & Equivalents stood at $393.6 million in 2022, then tumbled by 67.48% to $128.0 million in 2023, then skyrocketed by 199.32% to $383.2 million in 2024, then plummeted by 86.74% to $50.8 million in 2025.
- Its Cash & Equivalents was $50.8 million in Q3 2025, compared to $44.2 million in Q2 2025 and $105.2 million in Q1 2025.